Trans-Pacific partners TNI, Qianjiang advance MENK immunotherapy
By Cornelia Zou
Wednesday, August 20, 2014
HONG KONG – A Chinese pharmaceutical company and its American partner have announced their plan to accelerate collaboration on the development of cancer drugs, with an eye on launching clinical trials in China soon.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.